Global to push GA events into
skip to main content

Title: Anticancer therapy

A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.
Inventors:
Issue Date:
OSTI Identifier:
1349739
Assignee:
STC.UNM GFO
Patent Number(s):
9,610,371
Application Number:
14/669,313
Contract Number:
FG01-001NE23554
Resource Relation:
Patent File Date: 2015 Mar 26
Research Org:
STC.UNM, Albuquerque, NM (United States)
Sponsoring Org:
USDOE
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 59 BASIC BIOLOGICAL SCIENCES

Other works cited in this record:

Treatment of damaged bone marrow and dosage units therefor
patent, July 1990

Power-on reset circuit device for multi-level power supply sources
patent, May 1993

Complexes of functionalized tetraazacyclododecane chelates with bismuth, lead, ytriium, actinium, or lanthanide metal ions
patent, June 1995

Multi-tyrosinated somatostatin analogs
patent, January 1997

Peptides
patent, July 1997

Cyclic peptide somatostatin analogs
patent, August 1999

Conformationally constrained backbone cyclized somatostatin analogs
patent, April 2000

Highly sensitive multimeric nucleic acid probes
patent, June 2000

Somatostatin analogs for the treatment of cancer
patent, November 2001

Somatostatin analogs
patent, March 2002

Conformationally constrained backbone cyclized somatostatin analogs
patent, August 2005

Peptide compounds having improved binding affinity to somatostatin receptors
patent, October 2006

RGD (Arg-Gly-Asp) coupled to (neuro)peptides
patent, April 2007

Nephrotoxicity in Mice After Repeated Imaging Using 111In-Labeled Peptides
journal, May 2010
  • Melis, M.; Vegt, E.; Konijnenberg, M.
  • Journal of Nuclear Medicine, Vol. 51, Issue 6, p. 973-977
  • DOI: 10.2967/jnumed.109.074310

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
journal, November 2009
  • Rolleman, Edgar; Melis, Marleen; Valkema, Roelf
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, Issue 5, p. 1018-1031
  • DOI: 10.1007/s00259-009-1282-y

Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues
journal, July 2009
  • de Jong, Marion; Breeman, Wout; Kwekkeboom, Dik
  • Accounts of Chemical Research, Vol. 42, Issue 7, p. 873-880
  • DOI: 10.1021/ar800188e

Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats
journal, September 2006
  • Rolleman, Edgar; Krenning, Eric; Bernard, Bert
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 34, Issue 2, p. 219-227
  • DOI: 10.1007/s00259-006-0232-1

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
journal, April 2002
  • de Jong, Marion; Valkema, Roelf; Jamar, Francois
  • Seminars in Nuclear Medicine, Vol. 32, Issue 2, p. 133-140
  • DOI: 10.1053/snuc.2002.31027

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience
journal, April 2002
  • Valkema, Roelf; de Jong, Marion; Bakker, Willem H.
  • Seminars in Nuclear Medicine, Vol. 32, Issue 2, p. 110-122
  • DOI: 10.1053/snuc/2002.31025

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts
journal, February 2011
  • Walrand, Stephan; Barone, Raffaella; Pauwels, Stanislas
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, Issue 7, p. 1270-1280
  • DOI: 10.1007/s00259-011-1744-x

Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
journal, September 2010
  • Menda, Y.; O'Dorisio, M.; Kao, S.
  • Journal of Nuclear Medicine, Vol. 51, Issue 10, p. 1524-1531
  • DOI: 10.2967/jnumed.110.075226

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC
journal, December 2009
  • Sierra, Maribel; Agazzi, Alberto; Bodei, Lisa
  • Cancer Biotherapy & Radiopharmaceuticals, Vol. 24, Issue 6, p. 659-665
  • DOI: 10.1089/cbr.2009.0641

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
journal, April 2008
  • Bodei, Lisa; Cremonesi, Marta; Ferrari, Mahila
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 35, Issue 10, p. 1847-1856
  • DOI: 10.1007/s00259-008-0778-1

Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
journal, January 2008
  • Barone, Raffaella; Walrand, Stéphan; Konijnenberg, Mark
  • Nuclear Medicine Communications, Vol. 29, Issue 3, p. 283-290
  • DOI: 10.1097/MNM.0b013e3282f3d03e

Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors
journal, December 2006

Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial
journal, September 2004

Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas
journal, February 2004
  • Bodei, Lisa; Handkiewicz-Junak, Daria; Grana, Chiara
  • Cancer Biotherapy & Radiopharmaceuticals, Vol. 19, Issue 1, p. 65-71
  • DOI: 10.1089/108497804773391694

Assessment of Hepatic Toxicity from Treatment with 90Y-SMT 487 (OctreoTherâ„¢) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases
journal, August 2003
  • Bushnell, David; Menda, Yusuf; Madsen, Mark
  • Cancer Biotherapy & Radiopharmaceuticals, Vol. 18, Issue 4, p. 581-588
  • DOI: 10.1089/108497803322287664

90Y-DOTA-D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies
journal, January 2002
  • Paganelli, G.; Bodei, L.; Handkiewicz Junak, D.
  • Biopolymers, Vol. 66, Issue 6, p. 393-398
  • DOI: 10.1002/bip.10349

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
journal, July 2001
  • Waldherr, C.; Pless, M.; Maecke, H.
  • Annals of Oncology, Vol. 12, Issue 7, p. 941-945
  • DOI: 10.1023/A:1011160913619

Yttrium-90 DOTATOC: first clinical results
journal, October 1999
  • Otte, A.; Herrmann, R.; Heppeler, A.
  • European Journal of Nuclear Medicine and Molecular Imaging, Vol. 26, Issue 11, p. 1439-1447
  • DOI: 10.1007/s002590050476

Similar records in DOepatents and OSTI.GOV collections: